Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zhejiang Cancer Hospital
With
Chinese Academy of Medical Sciences
Fudan University
Peking University Cancer Hospital & Institute
Tianjin Medical University Cancer Institute and Hospital
Shandong Cancer Hospital and Institute
Jiangsu Cancer Institute & Hospital
Fujian Cancer Hospital
The First People's Hospital of Lianyungang
Primary
Evaluate the efficacy and safety of Endostar combined with concurrent chemo-radiotherapy (CCRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
Secondary
Measure changes in VEGF and other angiogenic cytokines and antiangiogenic factors in plasma samples from these patients.
Evaluate the application of CT perfusion imaging to determine changes in tumor vascular mophology and function during treatment.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
untreated histologic or cytologic of NSCLC verified
inoperable stage IIIA or IIIB NSCLC
measurable disease by RECIST
18\~70 years of age
an ECOG PS of 0 to 1
absolute neutrophil count (ANC) of ≥1500/μL, hemoglobin ≥10gm/dL, platelet ≥100,000/μL
serum creatinine ≤1.25 times of upper limit of normal (ULN), calculated creatinine clearance (CrCl) of ≥60ml/min
bilirubin 1.5×ULN, AST and ALT less than 2.5×ULN, alkaline phosphatase less than 5×ULN
forced vital capacity in 1 second (FEV1) higher than 0.8 L
